On the pharmacogenetics of non-small cell lung cancer treatment

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 3, 2016, Pages 307-317

  Santarpia, Mariacarmela ^a   Rolfo, Christian ^b   Peters, G J ^c   Leon, Leticia G ^d   Giovannetti, Elisa ^c,d  

^a UNIVERSITY OF MESSINA   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

EGFR inhibitors; lung cancer; methodological challenges; pemetrexed; pharmacogenetic studies

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER GENETICS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CHEMOSENSITIVITY; CLINICAL PRACTICE; COPY NUMBER VARIATION; DECISION MAKING; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENHANCER REGION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MINIMALLY INVASIVE PROCEDURE; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RNA PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PATIENT SELECTION; SURVIVAL RATE; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PEMETREXED; PHARMACOGENETICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84959151387     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1141894     Document Type: Review

References (100)

1. Dietel M, Jöhrens K, Laffert M, et al. update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther. 2015; 22: 417-430.
2. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000; 18: 2981-2989.
3. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 130: 160-165.
4. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
5. Gross S, Rahal R, Stransky N, et al. Targeting cancer with kinase inhibitors. J Clin Invest. 2015; 125: 1780-1789.
6. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
7. Sebastian M, Schmittel A, Reck M. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Eur Respir Rev. 2014; 23: 92-105.
8. Reck M, Mok T, Wolf J, et al. Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf. 2011; 10: 147-157.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
10. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14: 4275-4283.
11. Muller IB, De Langen AJ, Honeywell RJ, et al. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther. 2015 Jan 4:1-11. [Epub ahead of print
12. Rolfo C, Passiglia F, Castiglia M, et al. ALK and crizotinib: after the honeymoon.what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 2014; 3: 250-261.
13. Novello S, Capelletto E, Cortinovis D, et al. Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. Transl Lung Cancer Res. 2014; 3: 173-180.
14. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009; 5: 745-755.
15. Giovannetti E, Toffalorio F, De Pas T, et al. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics. 2012; 13: 1073-1086.
16. Igbokwe A, Lopez-Terrada DH. Molecular testing of solid tumors. Arch Pathol Lab Med. 2011; 135: 67-82.
17. Robert J, Le Morvan V, Giovannetti E, et al. On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer. 2014; 50: 2532-2543.
18. Wright CM, Larsen JE, Colosimo ML, et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in non small cell lung cancer. Eur Respir J. 2010; 35: 152-159.
19. Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-Treated advanced non-small-cell lung cancer patients. Ann Oncol. 2012; 23: 670-677.
20. Rose MC, Kostyanovskaya E, Huang RS. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics. 2014; 12: 198-209.
21. Patel SP, Schwaederle M, Daniels GA, et al. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015; 6 (32): 32602-32609.
22. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole exome sequencing (WES). J Clin Oncol. 2014; 32: 5s. suppl; abstr 11032
23. Jiang T, Ren S, Zhou C. Role of circulating-Tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015; 90 (2): 128-134.
24. Karachaliou N, Mayo-De Las Casas C, Queralt C, et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol. 2015; 1: 149-157.
25. Micke P, Edlund K, Holmberg L, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol. 2011; 6: 1833-1840.
26. Syrigos KN, Vansteenkiste J, Parikh P, et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol. 2010; 21: 556-561.
27. Huang YT, Lin X, Liu Y, et al. Cigarette smoking increases copy number alterations in non small-cell lung cancer. Proc Natl Acad Sci U S A. 2011; 108: 16345-16350.
28. Tekpli X, Landvik NE, Skaug V, et al. Functional effect of polymorphisms in 15q25 locus on CHRNA5 mRNA, bulky DNA adducts and TP53 mutations. Int J Cancer. 2013; 132 (8): 1811-1820.
29. Deben C, Deschoolmeester V, Lardon F, et al. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Crit Rev Oncol Hematol 2015; pii: S1040-8428(15)30089-5. 10.1016/j.critrevonc.2015.11.019. [Epub ahead of print
30. Galvani E, Peters GJ, Giovannetti E., Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs. 2011; 20: 1343-1356.
31. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007; 6: 404-417.
32. Giovannetti E, Lemos C, Tekle C, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol. Pharmacol. 2008; 73: 1290-1300.
33. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011; 104: 1594-1601.
34. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs. 2007; 25: 417-423.
35. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. Lung Cancer. 2011; 74: 132-138.
36. Sun JM, Han J, Ahn JS, et al. Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy. J Thorac Oncol. 2011; 6: 1392-1399.
37. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107: 1589-1596.
38. Wang L, Wang R, Pan Y, et al. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-Analysis. BMC Cancer. 2014; 14: 205.
39. Sun JM, Ahn JS, Jung SH, et al. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. J Clin Oncol. 2015; 33: 2450-2456.
40. Novello S, Scagliotti G, Torri V, et al. International tailored chemotherapy adjuvant trial: ITACA trial. J Clin Oncol. 2011; 29: e17514. suppl; abstr
41. Liu J, Schmitz JC, Lin X, et al. Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta. 2002; 1587 (2-3): 174-182.
42. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5-Terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct. 1995; 20: 191-197.
43. Wang X, Wang Y, Wang Y, et al. Association of thymidylate synthase gene 3-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci. 2013; 25: 20-25.
44. Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett. 2013; 5: 1165-1170.
45. Hu Q, Li X, Su C, et al. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med. 2012; 4: 1010-1016.
46. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 2038-2045.
47. Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012; 78: 92-99.
48. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010; 28: 614-619.
49. Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol. 2010; 5: 1346-1353.
50. Erdem L, Giovannetti E, Leon LG, et al. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012; 12: 1649-1659.
51. Galvani E, Alfieri R, Giovannetti E, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des. 2013; 19: 818-832.
52. Politi K, Ayeni D, Lynch T. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell. 2015; 27: 751-753.
53. Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007; 4: e125.
54. Moriai T, Kobrin MS, Hope C, et al. A variant epidermal growth factor receptor exhibits altered type alpha trans- forming growth factor binding and transmembrane signaling. P Natl Acad Sci USA. 1994; 91: 10217-10221.
55. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005; 65: 46-53.
56. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008; 8: 129-138.
57. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-Treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 2007; 120: 239-247.
58. Shitara M, Sasaki H, Yokota K, et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med. 2012; 4: 785-789.
59. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther. 2008; 83: 477-484.
60. Gebhardt F, Burger H, Brandt B. Modulation of EGFR gene tran- scription by secondary structures, a polymorphic repetitive se- quence and mutations-A link between genetics and epigenetics. Histol Histopathol. 2000; 15: 929-936.
61. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004; 64: 9139-9143.
62. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999; 274: 13176-13180.
63. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 2000; 60: 854-857.
64. Han S-W, Jeon YK, Lee KH, et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet Genom. 2007; 17: 313-319.
65. Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer. 2009; 66: 114-119.
66. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol. 2006; 1: 406-412.
67. Nie Q, Wang Z, Zhang GC, et al. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib. Eur J Pharmacol. 2007; 570: 175-181.
68. Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer. 2010; 67: 355-360.
69. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29: 4113-4120.
70. Lemos C, Kathmann I, Giovannetti E, et al. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer. 2009; 100: 1120-1127.
71. Harris SL, Gil G, Robins H, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A. 2005; 102 (45): 16297-16302.
72. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nat Genet. 2004; 36: 131-137.
73. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010; 9: 581-593.
74. Avan A, Maftouh M, Avan A, et al. SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC-letter. Clin Cancer Res. 2014; 20: 3623-3624.
75. Kim MJ, Kang HG, Lee SY, et al. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol. 2012; 105: 167-174.
76. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer. 2008; 98: 857-862.
77. Porcelli L, Lemos C, Peters GJ, et al. Intracellular trafficking of MDR transporters and relevance of SNPs. Curr Top Med Chem. 2009; 9: 197-208.
78. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 2007; 6: 432-438.
79. Lemos C, Giovannetti E, Zucali PA, et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011; 12: 159-170.
80. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-Targeted agents: is there a silver lining? J Clin Oncol. 2005; 23: 5235-5246.
81. Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 2009; 64: 346-351.
82. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008; 26: 1119-1127.
83. Morales-Espinosa D, García-Román S, Karachaliou N, et al. Pharmacogenomics in the treatment of lung cancer: an update. Pharmacogenomics. 2015; 16 (15): 1751-1760.
84. Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014; 89: 300-313.
85. Galvani E, Toffalorio F, Peters GJ, et al. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"? Curr Pharm Des. 2014; 20: 3863-3874.
86. Kelly PJ, Stallard N, Whittaker JC. Statistical design and analysis of pharmacogenetic trials. Stat Med. 2005; 24: 1495-1508.
87. Maitland ML, Ratain MJ, Cox NJ., Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol. 2007; 25: 4513-4515.
88. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice. Nat Rev Drug Discov. 2005; 4: 639-647.
89. Le Morvan V, Bellott R, Moisan F, et al. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-À-vis the NCI-60 panel. Pharmacogenomics. 2006; 7: 843-852.
90. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-607.
91. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483: 570-575.
92. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010; 11: 241-246.
93. Wu X, Ye Y, Rosell R, et al., et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011; 103: 817-825.
94. Guchelaar HJ, Gelderblom H, Van Der Straaten T, et al. Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing. Clin Pharmacol Ther. 2014; 95: 383-385.
95. U.S. Food and Drug Administration. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics. Accessed 11 January 2016.
96. Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012; 81: 103-122.
97. Robles AI, Arai E, Mathé EA, et al. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol. 2015; 10: 1037-1048.
98. Okayama H, Schetter AJ, Ishigame T, et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev. 2014; 23: 2884-2894.
99. Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, et al. Real-Time liquid biopsies become a reality in cancer treatment. Ann Transl Med. 2015; 3: 36.
100. Rolfo C, Fanale D, Hong DS, et al. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. 2014; 15: 475-485.